Your browser doesn't support javascript.
loading
Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.
Henderson, Rory; Anasti, Kara; Manne, Kartik; Stalls, Victoria; Saunders, Carrie; Bililign, Yishak; Williams, Ashliegh; Bubphamala, Pimthada; Montani, Maya; Kachhap, Sangita; Li, Jingjing; Jaing, Chuancang; Newman, Amanda; Cain, Derek; Lu, Xiaozhi; Venkatayogi, Sravani; Berry, Madison; Wagh, Kshitij; Korber, Bette; Saunders, Kevin O; Tian, Ming; Alt, Fred; Wiehe, Kevin; Acharya, Priyamvada; Alam, S Munir; Haynes, Barton F.
Afiliação
  • Henderson R; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Anasti K; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
  • Manne K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Stalls V; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Saunders C; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Bililign Y; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Williams A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Bubphamala P; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Montani M; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Kachhap S; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Li J; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Jaing C; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Newman A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Cain D; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Lu X; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Venkatayogi S; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
  • Berry M; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Wagh K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Korber B; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Saunders KO; Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
  • Tian M; The New Mexico Consortium, Los Alamos, NM, 87544 USA.
  • Alt F; Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
  • Wiehe K; The New Mexico Consortium, Los Alamos, NM, 87544 USA.
  • Acharya P; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
  • Alam SM; Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
  • Haynes BF; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, 02115.
bioRxiv ; 2023 Dec 30.
Article em En | MEDLINE | ID: mdl-38168268
ABSTRACT
Vaccine development targeting rapidly evolving pathogens such as HIV-1 requires induction of broadly neutralizing antibodies (bnAbs) with conserved paratopes and mutations, and, in some cases, the same Ig-heavy chains. The current trial-and-error search for immunogen modifications that improve selection for specific bnAb mutations is imprecise. To precisely engineer bnAb boosting immunogens, we used molecular dynamics simulations to examine encounter states that form when antibodies collide with the HIV-1 Envelope (Env). By mapping how bnAbs use encounter states to find their bound states, we identified Env mutations that were predicted to select for specific antibody mutations in two HIV-1 bnAb B cell lineages. The Env mutations encoded antibody affinity gains and selected for desired antibody mutations in vivo. These results demonstrate proof-of-concept that Env immunogens can be designed to directly select for specific antibody mutations at residue-level precision by vaccination, thus demonstrating the feasibility of sequential bnAb-inducing HIV-1 vaccine design.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos